Quarterly Report (10-q)

Date : 08/14/2019 @ 7:49PM
Source : Edgar (US Regulatory)
Stock : Imaging3, Inc. (QB) (IGNG)
Quote : 0.0775  0.0025 (3.33%) @ 9:00PM

Quarterly Report (10-q)

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For Quarterly Period Ended June 30, 2019

 

or

 

[  ] TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Transition period from ______________to ______________

 

Commission File Number: 000-50099

 

IMAGING3, INC.

(Exact name of registrant as specified in its charter)

 

CALIFORNIA   95-4451059
(State or other jurisdiction of   (I.R.S. Employer
incorporation or organization)   Identification No.)

 

10866 Wilshire Blvd. Suite 225, Los Angeles, CA 90024

(Address of principal executive offices) (Zip Code)

 

310-575-1175

Registrant’s telephone number, including area code

 

 

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

Yes [X] No [  ]  

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

 

Yes [X] No [  ]  

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check One).

 

Large accelerated filer [  ] Accelerated filer [  ]
Non-accelerated filer [  ] Smaller reporting company [X]
(Do not check if a smaller reporting company)      

 

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

 

Yes [  ] No [X]  

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock as of the latest practicable date.

 

As of August 8, 2019, the number of shares outstanding of the registrant’s class of common stock was 464,166,789.

 

 

 

 
 

 

TABLE OF CONTENTS

 

    Page
PART I. FINANCIAL INFORMATION  
Item 1. Condensed Financial Statements (Unaudited) 3
  Condensed Balance Sheets at June 30, 2019 (Unaudited) and December 31, 2018 3
  Condensed Statements of Operations for the Three Months and Six Months Ended June 30, 2019 and 2018 (Unaudited) 4
  Condensed Statements of Cash Flows for the Six Months Ended June 30, 2019 and 2018 (Unaudited) 5
  Notes to Condensed Financial Statements (Unaudited) 6
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 15
Item 3. Quantitative and Qualitative Disclosures About Market Risk 20
Item 4. Controls and Procedures 20
     
PART II. OTHER INFORMATION  
Item 1. Legal Proceedings  
Item 1A. Risk Factors 21
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 21
Item 3. Defaults Upon Senior Securities 21
Item 4. Mine Safety Disclosures 21
Item 5. Other Information 21
Item 6. Exhibits 21
     
SIGNATURES 22

 

2
 

 

PART I. FINANCIAL INFORMATION

 

Item 1. Condensed Financial Statements

 

IMAGING3, INC.

BALANCE SHEETS

 

    June 30, 2019     December 31, 2018  
    (Unaudited)     (Audited)  
             
ASSETS                
                 
CURRENT ASSETS:                
Cash and cash equivalents   $ 47,539     $ 14,214  
Other receivables – related party, Note 9     264,050       -  
Total current assets     311,589       14,214  
NON-CURRENT ASSETS:                
Prepaid financing costs     1,097,336          
                 
TOTAL ASSETS   $ 1,408,925     $ 14,214  
                 
LIABILITIES AND STOCKHOLDERS’ DEFICIT                
                 
CURRENT LIABILITIES:                
Accounts payable   $ 586,433     $ 703,518  
Administrative claims payable     1,113,708       1,113,708  
Accrued expenses     174,684       372,773  
Subscriptions payable     1,860,679       289,283  
Derivative liability     591,309       677,990  
Convertible notes payable, net of discount of $- and $179,307     619,918       2,167,107  
Total current liabilities     4,946,731       5,324,379  
LONG TERM LIABILITIES                
Long-term note payable, net of discount of $575,000     25,000       -  
                 
TOTAL LIABILITIES     4,971,731       5,324,379  
COMMITMENTS AND CONTINGENCIES, Note 8                
                 
STOCKHOLDERS’ DEFICIT:                
      -       -  
Common stock and additional paid-in capital authorized 1,000,000,000 shares, no par value and 68,881,437 and 40,426,983 issued and outstanding as of June 30, 2019, and December 31, 2018, respectively     19,901,130       15,944,948  
Accumulated deficit     (23,463,936 )     (21,255,113 )
Total stockholders’ deficit     (3,562,806 )     (5,310,165 )
Total liabilities and stockholders’ deficit   $ 1,408,925     $ 14,214  

 

The accompanying notes form an integral part of these unaudited financial statements

 

3
 

 

IMAGING3, INC.
CONDENSED STATEMENTS OF OPERATIONS

(UNAUDITED)

 

   

Three months ended

June 30, 2019

   

Three months ended

June 30, 2018

   

Six months ended

June 30, 2019

   

Six months ended

June 30, 2018

 
                         
Net revenues   $ -     $ -     $ -     $ -  
                                 
Cost of goods sold     -       -       -       -  
Gross profit (loss)     -       -       -       -  
                                 
Operating expenses:                                
General and administrative expenses     685,225       334,939       880,550       6,006,236  
Total operating expenses     685,225       334,939       880,550       6,006,236  
                                 
Loss from operations     (685,225 )     (334,939 )     (880,550 )     (6,006,236 )
                                 
Other income (expense):                                
Interest expense     (317,824 )     (225,109 )     (366,120 )     (530,402 )
Change in value of derivative instruments     14,730,082       742,248       (903,397 )     (3,607 )
Gain (loss) on extinguishment of debt     (8,830 )     (1,026,071 )     (58,756 )     (1,033,029 )
Other income (expense)     -       (22,035 )     -       (22,035 )
Total other income (expense)     14,403,428       (530,967 )     (1,328,273 )     (1,589,073 )
                                 
Income (loss) before income taxes     13,718,203       (865,906 )     (2,208,823 )     (7,595,309 )
                                 
Provision for income taxes     -       800       -       800  
                                 
Net income (loss)   $ 13,718,203     $ (866,706 )   $ (2,208,823 )   $ (7,596,109 )
                                 
Net income (loss) per share - Basic   $ 0.22     $ (0.02 )   $ (0.04 )   $ (0.27 )
Net income (loss) per share - Diluted   $ 0.15     $ (0.02 )   $ (0.04 )   $ (0.27 )
Weighted average common stock outstanding - Basic     62,341,213       38,844,783       51,900,759       28,574,832  
Weighted average common stock outstanding - Diluted     90,221,039       38,844,783       51,900,759       28,574,832  

 

The accompanying notes form an integral part of these unaudited financial statements.

 

4
 

 

IMAGING3, INC.

CONDENSED STATEMENTS OF CASH FLOWS FOR THE SIX MONTHS ENDED

JUNE 30, 2019 AND 2018

(UNAUDITED)

 

    Six months ended     Six months ended  
    June 30, 2019     June 30, 2018  
CASH FLOWS FROM OPERATING ACTIVITIES:                
Net income (loss)   $ (2,208,823 )   $ (7,596,109 )
Adjustments to reconcile net income (loss) to net cash used for operating activities:                
Non-cash interest     177,523       450,217  
(Gain) loss on extinguishment of debt     58,755       6,959  
Change in value of derivatives     903,397       3,532  
Shares issued for services     350,469       5,442,076  
Warrants issued for services                
Increase / (decrease) in current liabilities:                
Accounts payable and accrued expenses     (45,730 )     1,185,702  
Net cash used for operating activities     (764,409 )     (507,623 )
                 
CASH FLOWS FROM INVESTING ACTIVITIES:                
Advance to future acquisition     (300,000 )     -  
Repayment of advance     35,950       -  
Net cash used for investing activities     264,050       -  
                 
CASH FLOWS FROM FINANCING ACTIVITIES:                
Proceeds from issuance of notes payable     630,000       25,000  
Cash paid in settlement     (200,000 )     -  
Repayment of notes payable             (10,000 )
Proceeds from sale of stock, net of offering costs     631,783       493,223  
Net cash provided from financing activities     1,061,783       508,223  
                 
NET INCREASE (DECREASE) IN CASH & CASH EQUIVALENTS     33,325       600  
                 
CASH & CASH EQUIVALENTS, BEGINNING BALANCE     14,214       3,594  
                 
CASH & CASH EQUIVALENTS, ENDING BALANCE   $ 47,539     $ 4,194  
SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING ACTIVITY                
Notes and accrued interest converted to common stock   $ 1,703,423     $ 40,900  
Promissory notes issued for no cash consideration   $       $ 789,090  

 

The accompanying notes form an integral part of these unaudited financial statements

 

5
 

 

IMAGING3, INC.

Notes to Condensed Financial Statements

(Unaudited)

 

1. ORGANIZATION AND DESCRIPTION OF BUSINESS

 

Imaging3, Inc. (the “Company”, “us”, “we”, “Imaging3”) is a corporation incorporated on October 29, 1993 as Imaging Services, Inc. in the state of California. The Company filed a certificate of amendment of articles of incorporation to change its name to Imaging3, Inc. on August 20, 2002. In March of 2018, the Company incorporated in Delaware.

 

The Company is a development stage medical device company. The Company has developed a portable proprietary imaging technology designed to produce 3D x-ray images in real time. The Company’s devices have the potential to use less radiation and require less specialized power sources than many currently available x-ray imaging devices. The Company’s lead device, the Dominion Smartscan, for which the Company plans to submit a 510K application with the FDA in 2020, will be easily transportable and works off conventional household current. While the primary focus is applications for the healthcare industry, there are many potential non-healthcare related uses for the Company’s technology, including agriculture and security.

 

2. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

On September 13, 2012 (the “Petition Date”), the Company filed a voluntary petition with the federal bankruptcy court in Los Angeles, California, to enter bankruptcy under Chapter 11 of the United States Bankruptcy Code. On or about July 15, 2013, our Plan of Reorganization was approved by the United States Bankruptcy Court. On July 30, 2013, we emerged from bankruptcy and continued operations under the terms and conditions of our Bankruptcy Reorganization Plan as it applies to post bankruptcy operations. For accounting purposes, management deemed the effective date of the Chapter 11 Plan (the “Plan”) to be June 30, 2013. The Company’s operations between July 1, 2013 and July 30, 2013 were not significant. The Plan adopted by Imaging3, Inc. is a reorganizing plan. Payments under the Plan were made by utilizing existing cash on hand, borrowings on a secured and unsecured basis, future cash flow, if any, capital raised through the sale of our common stock in private placements, and by conversion of debt to equity.

 

Upon emergence from bankruptcy, Imaging3 adopted fresh-start accounting which resulted in Imaging3 becoming a new entity for financial reporting purposes. Imaging3 applied fresh start accounting as of July 1, 2013. As a result of the application of fresh start accounting and the effects of the implementation of the plan of reorganization, the financial statements on or after July 1, 2013 are not comparable with the financial statements prior to that date.

 

The accompanying unaudited interim financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission for the presentation of interim financial information, but do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2018. The Company follows the same accounting policies in preparation of interim reports. Results of operations for the interim periods are not indicative of annual results

 

Use of Estimates

 

In preparing financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

6
 

 

Cash and Cash Equivalents

 

The Company considers all liquid investments with a maturity of three months or less from the date of purchase that are readily convertible into cash to be cash equivalents. The Company maintains its cash in bank deposit accounts that may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company had no cash equivalents at June 30, 2019 or December 31, 2018.

 

Revenue Recognition

 

Effective January 1, 2018, the Company adopted the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 supersedes the revenue recognition requirements in FASB Accounting Standards Codification (“ASC”) 605, Revenue Recognition, and is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. It also requires additional disclosure about the nature, amount, timing, and uncertainty of revenue, cash flows arising from customer contracts, including significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. The adoption of ASU 2014-09, using the modified retrospective approach, had no significant impact on the Company’s results of operation, cash flows or financial position.

 

Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products or providing services. All revenue is recognized when the Company satisfies its performance obligations under the contract. The majority of the Company’s contracts have a single performance obligation and are short term in nature. Generally, the Company extends credit to its customers and does not require collateral. The Company performs ongoing credit evaluations of its customers and historic credit losses have been within management’s expectations. The Company has a revenue receivables policy for service and warranty contracts. Equipment sales usually have a one-year warranty of parts and service. After a one-year period, the Company contacts the buyer to initiate the sale of a new warranty contract for one year. Warranty revenues are deferred and recognized on a straight-line basis over the term of the contract or as services are performed.

 

Basic and Diluted Net Income Per Share

 

Basic net income per share is based upon the weighted average number of common shares outstanding. Diluted net income per share is based on the assumption that all dilutive convertible shares and stock options were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. During 2018 and 2019, potentially dilutive securities were excluded from the computation of weighted average shares outstanding-diluted because their effect was anti-dilutive.

 

Derivative Financial Instruments

 

The Company generally does not use derivative financial instruments to hedge exposures to cash-flow risks or market-risks that may affect the fair values of its financial instruments. The Company utilizes various types of financing to fund its business needs, including convertible notes and warrants and other instruments not indexed to our stock. The Company is required to record its derivative instruments at their fair value. Changes in the fair value of derivatives are recognized in earnings in accordance with ASC 815. The Company’s only asset or liability measured at fair value on a recurring basis is its derivative liability associated with warrants to purchase common stock and convertible notes.

 

Fair Value of Financial Instruments

 

The fair value accounting standard creates a three-level hierarchy to prioritize the inputs used in the valuation techniques to derive fair values. The basis for fair value measurements for each level within the hierarchy is described below with Level 1 having the highest priority and Level 3 having the lowest.

 

Level 1: Observable prices in active markets for identical assets or liabilities.

 

Level 2: Observable prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in the market.

 

Level 3: Valuations derived from valuation techniques in which one or more significant inputs are unobservable. These unobservable assumptions reflect estimates of assumptions that market participants would use in pricing the asset or liability. Valuation techniques include use of option pricing models, discounted cash flow models, and similar techniques.

 

7
 

 

The Company had the following assets or liabilities measured at fair value on a recurring basis at June 30, 2019 and December 31, 2018 respectively.

 

    Level 1     Level 2     Level 3     Total  
Derivative Liabilities June 30, 2019   $ -     $ -     $ 591,309     $ 591,309  
Derivative Liabilities December 31, 2018   $ -     $ -     $ 677,990     $ 677,990  

 

Income Taxes

 

The Company accounts for income taxes in accordance with ASC 740-10, “Income Taxes” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns.

 

Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The provision for income taxes represents the tax payable for the period and the change during the period in deferred tax assets and liabilities.

 

Research and Development

 

Costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with FASB ASC 730-10. Included in research and development costs are operating costs, facilities, supplies, external services, clinical trial and manufacturing costs, and overhead directly related to the Company’s research and development operations, as well as costs to acquire technology licenses.

 

Recent Accounting Pronouncements

 

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) , which supersedes existing guidance on accounting for leases in “Leases (Topic 840)” and generally requires all leases to be recognized in the consolidated balance sheet. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018; early adoption is permitted. The provisions of ASU 2016-02 are to be applied using a modified retrospective approach. The adoption of this standard had no material impact on the Company’s financial position or results of operations.

 

In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting . This ASU affects entities that issue share-based payment awards to their employees. The ASU is designed to simplify several aspects of accounting for share-based payment award transactions which include – the income tax consequences, classification of awards as either equity or liabilities, classification on the statement of cash flows and forfeiture rate calculations. ASU 2016-09 became effective for the Company in the first quarter of fiscal 2018. The adoption of this standard had no material impact on the Company’s financial position or results of operations.

 

8
 

 

In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception, (ASU 2017-11). Part I of this update addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible Form instruments) with down round features that require fair value measurement of the entire instrument or conversion option. Part II of this update addresses the difficulty of navigating Topic 480, Distinguishing Liabilities from Equity, because of the existence of extensive pending content in the FASB Accounting Standards Codification. This pending content is the result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable noncontrolling interests. The amendments in Part II of this update do not have an accounting effect. This ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. The adoption of this standard had no material impact on the Company’s financial position or results of operations.

 

3. INCOME TAXES

 

The Company’s book losses and other timing differences result in a net deferred income tax benefit which is offset by a valuation allowance for a net deferred asset of zero. The Company has concluded, in accordance with the applicable accounting standards, that it is more likely than not that the Company may not realize the benefit of all of its deferred tax assets. Accordingly, management has provided a 100% valuation allowance against its deferred tax assets until such time as management believes that its projections of future profits as well as expected future tax rates make the realization of these deferred tax assets more-likely-than-not. Significant judgment is required in the evaluation of deferred tax benefits and differences in future results from our estimates could result in material differences in the realization of these assets. The Company has recorded a full valuation allowance related to all of its deferred tax assets. The Company has performed an assessment of positive and negative evidence regarding the realization of the net deferred tax asset in accordance with FASB ASC 740-10, “Accounting for Income Taxes.” This assessment included the evaluation of scheduled reversals of deferred tax liabilities, the availability of carry forwards and estimates of projected future taxable income. The availability of the Company’s net operating loss carry forwards is subject to limitation if there is a 50% or more change in the ownership of the Company’s stock. The provision for income taxes consists of the state minimum tax imposed on corporations of $800. The Company has adopted guidance issued by the FASB that clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold of more likely than not and a measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In making this assessment, a company must determine whether it is more likely than not that a tax position will be sustained upon examination, based solely on the technical merits of the position and must assume that the tax position will be examined by taxing authorities. The Company’s policy is to include interest and penalties related to unrecognized tax benefits in income tax expense. The Company has not recognized any unrecognized tax benefits and does not have any interest or penalties related to uncertain tax positions as of December 31, 2018 or June 30, 2019.

 

4. NOTES PAYABLE

 

During the first quarter of 2018, the Company issued a promissory note in the amount of $10,000 that bears interest of 10%. The note matured as of April 15, 2018 and was paid back with cash.

 

During the first quarter of 2019, the Company issued two short-term promissory notes in the amount of $30,000 that bears interest at $6,000 per month. The notes matured within twenty days of issuance but are extendable at the Company’s option and were converted to shares as of July 16, 2019.

 

During 2018, debt and accrued interest in the amount of $574,524 were converted to 6,811,151 shares of common stock. As a result of these conversions, the Company recognized approximately $100,000 as a gain on extinguishment of debt, accrued interest, and derivative liabilities.

 

During the first quarter ended March 31, 2019, debt and accrued interest in the amount of $54,338 were converted to 14,027,800 shares of common stock. As a result of these conversions, the Company recognized approximately $50,000 as a loss on extinguishment of debt, accrued interest, and derivative liabilities.

 

9
 

 

During the second quarter ended June 30, 2019, debt and accrued interest in the amount of $1,703,423 were converted to 15,407,367 shares of common stock, of which 6,601,669 have been issued. As a result of these conversions, the Company recognized approximately $9,000 as a loss on extinguishment of debt, accrued interest, and derivative liabilities during the second quarter.

 

Amortization of note discounts amounted to $179,307 during the six months ended June 30, 2018 and $25,000 for the six months ended June 30, 2019.

 

On May 31, 2019, the Company executed a Securities Purchase Agreement (the “SPA”), with Auctus Fund, LLC of Boston MA (the “Investor”) pursuant to the terms of which IGNG will sell $4,000,000 of Convertible Notes (the “Notes”) and issue $6,200,000 of callable warrants (“the Warrants”) to the Investor. Pursuant to the SPA, Auctus will purchase the $4,000,000 of Notes from IGNG in four tranches as follows: $600,000.00 at the SPA closing, which was funded on June 6, 2019; the second tranche of $1,400,000.00 will be funded by Auctus on the day IGNG files its required registration statement on Form S-1 registering the IGNG shares underlying tranches 1 and 2 (the “Registration Statement”); the third tranche will be funded the day the SEC declares the Registration Statement effective and the fourth tranche will be funded 90 Days after the Effective Date. The Notes have a two-year term and will bear interest at 10%. The notes are redeemable at any time between the date of issuance and maturity at 150% of face value. The Notes will be convertible into shares of IGNG common stock at 95% of the mathematical average of the five lowest trading prices for IGNG common stock on the OTCQB for the period from the Closing to the maturity date of the Note being converted less $0.01 for conversions at less than $0.15 and less $0.02 for conversions at more than $0.15.

 

5. STOCKHOLDERS’ EQUITY

 

Preferred Stock

 

The Company has authorized 1,000,000 shares of preferred stock. During 2017, 2,000 shares of preferred shares were cancelled. As of June 30, 2019, and December 31, 2018, there are no shares of preferred stock outstanding.

 

Common Stock

 

The Company is authorized to issue 1,000,000,000 shares of no-par value common stock.

 

During the six months ended June 30, 2018, the Company issued a total of 2,904,171 shares of common stock for cash in the amount of $493,223 and 18,058,539 shares were issued for services rendered valued at $5,442,076. During the six months ended June 30, 2018, 3,000,000 of these shares were cancelled.

 

During the six months ended June 30, 2019, the Company issued 10,544,985 shares for $273,283 of subscription payable received before December 31, 2018 and $358,500 for cash during the current year, 20,629,469 shares related to conversions of notes payable of $1,945,615. During the six months ended June 30, 2019, 8,000,000 shares of stock to a former officer were canceled. The Company awarded directors, officers and key consultants 5,750,000 shares for services rendered. 5,280,000 of these shares were issued during the quarter ending June 30, 2019 totaling an amount of $87,800. At June 30, 2019, the company is also in the process of issuing 14,811,440 shares of common stock for the balance of subscription payable at June 30, 2019, which is mainly comprised of debt conversion.

 

As of June 30, 2019, there were approximately 591 record holders of our common stock, not including shares held in “street name” in brokerage accounts which is unknown. As of June 30, 2019, there were 68,881,437 shares of our common stock outstanding on record.

 

Stock Option Plan

 

During 2014, the Board of Directors adopted, and the shareholders approved, the 2014 Stock Option Plan under which a total of 27,000,000 shares of common stock had been reserved for issuance. The Stock Option Plan will terminate in September 2024.

 

10
 

 

Stock Options

 

Transactions in 2018   Quantity     Weighted-
Average
Exercise
Price
Per
Share
    Weighted-
Average Remaining
Contractual
Life
 
Outstanding, December 31, 2018     250,000     $ 1.00       6.57  
Granted                        
Exercised                        
Cancelled/Forfeited                        
Outstanding, June 30, 2019     250,000     $ 1.00       6.08  
Exercisable, June 30, 2019     250,000     $ 1.00       6.08  
                         
Transactions in FY2018                        
                         
Outstanding, December 31, 2017     250,000     $ 1.00       7.57  
Granted                        
Exercised                        
Cancelled/Forfeited                        
Outstanding, December 31, 2018     250,000     $ 1.00       6.57  
Exercisable, December 31, 2018     250,000     $ 1.00       6.57  

 

As of June 30, 2019, former employees of the Company hold options to purchase 250,000 shares of common stock at an exercise price of $1.00.

 

6. WARRANTS

 

Following is a summary of warrants outstanding at June 30, 2019:

 

Number of Warrants   Exercise Price     Expiration Date
37,500   $ 0.10     April 2022
500,000   $ 0.10     August 2022
575,000   $ 0.10     April 2023
125,000   $ 0.10     May 2023
162,500   $ 0.10     August 2023
2,800,000   $ 0.40     May 2022
302,776   $ 0.10     January 2024
12,000,000   $ 0.10     March 2021
2,160,000   $ 0.10     June 2021
16,000,000   $ 0.125     May 2021
15,000,000   $ 0.15     May 2021
8,000,000   $ 0.25     May 2021
200,000   $ 0.10     October 2020

 

During the six months ended June 30, 2019, the Company issued of 8,960,000 warrants to purchase 8,960,000 shares of the Company’s common stock at an exercise price of $0.10 per share for a period of two years from the date of issuance. The Company also issued 16,000,000 warrants to purchase 16,000,000 shares of the Company’s common stock at an exercise price of $0.125 per share, 15,000,000 warrants to purchase 15,000,000 shares of the Company’s common stock at an exercise price of $0.15 per share, 8,000,000 warrants to purchase 8,000,000 shares of the Company’s common stock at an exercise price of $0.25 per share for a period of two year from the date of issuance.

 

11
 

 

7. DERIVATIVE LIABILITIES

 

The Company’s only asset or liability measured at fair value on a recurring basis was its derivative liability associated with warrants to purchase common stock and the conversion features embedded in convertible promissory notes.

 

In connection with financing transactions, the Company issued warrants to purchase common stock and convertible promissory notes. These instruments included provisions that could result in a reduced exercise price based on specified full-ratchet anti-dilution provisions. The “reset” provisions were triggered in the event the Company subsequently issued common stock, stock warrants, stock options or convertible debt with a stock price, exercise price or conversion price lower than contractually specified amounts. Upon triggering the “reset” provisions, the exercise / conversion price of the instrument will be reduced. Accordingly, pursuant to ASC 815, these instruments were not considered to be solely indexed to the Company’s own stock and were not afforded equity treatment.

 

The following table summarizes activity in the Company’s derivative liability during the six months ended June 30, 2019 and the year ended December 31, 2018:

 

12-31-18 Balance   $ 677,990  
Creation     558,879  
Reclassification of equity     (1,548,956 )
Change in Value     903,396  
6-30-19 Balance   $ 591,309  
         
12-31-2017 Balance   $ 701,347  
Creation     -  
Reclassification to Equity     (202,996 )
Change in Value     179,639  
12-31-2018 Balance   $ 677,990  

 

The Company classifies the fair value of these derivative liabilities under level 3 of the fair value hierarchy of financial instruments. The fair value of the derivative liability was calculated using a Black Scholes model. The Company’s stock price and estimates of volatility are the most sensitive inputs in validation of assets and liabilities at fair value. The liabilities were measured using the following assumptions:

 

Term   0.01 years -5.0 years  
Dividend Yield     0 %
Risk-free rate     2.33% - 2.49 %
Volatility     65-168 %

 

8. COMMITMENTS AND CONTINGENCIES

 

Bankruptcy Closure

 

On January 31, 2017, United States Bankruptcy Judge for the Central District of California, Neil Bason, granted the Company’s unopposed motion for entry of final decree and also granted approval of the two stipulations regarding payment of court-approved fees. As a result, the Imaging3 Chapter 11 proceeding is now closed. The Company is no longer subject to the jurisdiction of the Bankruptcy Court, and the case cannot be converted to a Chapter 7 proceeding.

 

Alpha and Brio Settlement

 

On Monday, April 15, 2019, Imaging3, Alpha Capital Anstalt (“Alpha”) and Brio Capital Master Fund (“Brio”) agreed to terms settling the outstanding judgment against the Company, issued by the United States District Court for the Southern District of New York (the “Court”) on July 27, 2018 (the “Agreement”). The Court awarded Alpha $804,770.08 and Brio $669,805.43, respectively. On June 6, 2019 per terms of the Agreement, the Company paid $100,000 cash to both Alpha and Brio at the time of the closing of the Acquisition. The balance of the judgments will be converted to IGNG restricted common shares at the conversion price of $0.164 per share, translating to 4,191,070 (four million, one hundred, ninety thousand, and seventy) Shares of IGNG’s common stock to Alpha and 3,514,628 (three million, five hundred fourteen thousand, six hundred and twenty) Shares to Brio, which is included in the subscription payable. The settlement resulted in a gain of $12,075 recorded in the second quarter of 2019.

 

12
 

 

9. RELATED PARTY TRANSACTIONS

 

On June 7, 2019, the Company advanced $300,000 to Grapefruit Boulevard Investments (“Grapefruit”), an entity substantially owned by two officers of the Company. On June 28, 2019, $35,950 of the advance was repaid. The balance of $264,050 is included in other receivables as of June 30, 2019. As described in Note 10, On July 10, 2019, the Company completed a transaction by which IGNG was acquired in a reverse acquisition by Grapefruit.

 

10. SUBSEQUENT EVENTS

 

Administrative Claim of Greenberg Glusker Fields Claman & Machtinger LLP

 

On Friday July 5, 2019 the Company and Greenberg Glusker Fields Claman & Machtinger, LLP executed a Settlement Agreement (the “Greenberg Settlement Agreement”), with its former bankruptcy counsel and largest trade creditor Greenberg Glusker Fields Claman & Machtinger LLP (“GG”). The Greenberg Settlement Agreement calls for IGNG/Grapefruit to liquidate the outstanding GG balance of $1,245,380.00 (the “Balance”) by the payment of $204,000 to GG in three payments of $68,000.00 to be made by no later than November 30, 2019 and the immediate issuance of 6,351,126 IGNG common shares (The “Settlement Shares”) at an agreed value of $.164 per share to GG. The Settlement Shares will be the subject of a Section 3(a)(10) of the Securities Act of 1933 action (the “3(a)(10) Action”) to be expeditiously filed by GG, by which the Court hearing the 3(a)(1) action will be asked to approve the Agreement and after such approval the Settlement Shares shall be immediately eligible for resale in the public markets. The Greenberg Settlement Agreement calls for the issuance of “Make Whole” shares to GG, if after the sale of all the Settlement Shares by GG in the public market it fails to realize sufficient funds to liquidate the balance. The Greenberg Settlement Agreement also contains a “leak out” provision limiting sales of the Settlement Shares by GG to ensure that such sale do not disrupt the market for IGNG shares while such shares are being liquidated.

 

Final Closing on Grapefruit Acquisition

 

On Wednesday July 10, IGNG closed the Share Exchange after the completion of all conditions subsequent contemplated by the Share Exchange Agreement among the parties thereto (the “SEA”), including the execution of the Greenberg Settlement Agreement as set forth above, by which IGNG was acquired in a reverse acquisition (the “Acquisition”) by the former shareholders of Grapefruit Boulevard Investments, Inc (“Grapefruit”)., a California corporation and privately held cannabis products company based in Westwood, Los Angeles, CA. Under the terms of the SEA executed on May 31, 2019 IGNG became obligated to issue to Grapefruit’s existing shareholders that number of newly issued restricted IGNG common shares such that the former Grapefruit shareholders (now new IGNG shareholders) will own approximately 81% of the post-Acquisition IGNG common shares and the current IGNG shareholders will retain 19% of the post-Acquisition IGNG common shares. At the time of the execution of the SEA, IGNG had approximately eighty-five million two hundred eighteen thousand two hundred forty-nine (85,218,249) outstanding shares of common stock. Therefore, IGNG issued to Grapefruit’s shareholders three hundred sixty-two million nine hundred seventy-nine thousand one hundred fourteen (362,979,114) IGNG common shares to Grapefruit’s current shareholder on a pro rata basis with their current ownership of Grapefruit of which Bradley Yourist and Daniel J. Yourist own a combined 72.26% or approximately two hundred fifty nine million nine hundred sixty seven thousand one hundred thirty six (259,967,136) shares. In addition, IGNG issued approximately twenty-three million three hundred thirty-seven thousand two hundred fifty-two (23,337,251) new restricted common shares to an advisor to Grapefruit in connection with structuring of the Acquisition and the Investment. As a result, at the conclusion of the Acquisition, IGNG has issued a total of approximately four hundred seventy-one million six hundred twenty-six thousand eight hundred fourteen 471,626,814 common shares issued and outstanding.

 

Within 75 days of the Closing the Company shall file a Form 8-K with the SEC which will include, along with all other required disclosures, pro forma consolidated financial statements of IGNG and GBI.

 

Conversion of Liability

 

In July 2019, a former chairman and a director of the company converted accrued compensation in the amount of $105,000 for 2,200,000 shares and 4,400,000 warrants exercisable at $0.10 per share. 

 

13
 

 

11. GOING CONCERN

 

The Company’s financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has historically incurred net losses and as of June 30, 2019 had an accumulated deficit totaling $23.5 million. During the six months ended June 30, 2019 and the years ended December 31, 2018 and 2017, the Company utilized an aggregate of $1.8 million of cash in operating activities and incurred an aggregate net loss of $18.7 million. The continuing losses have adversely affected the liquidity of the Company.

 

In view of the matters described in the preceding paragraph, recoverability of a major portion of the recorded asset amounts shown in the accompanying balance sheet is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to raise additional capital, obtain financing and to succeed in its future operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary as a result of the Company’s going concern uncertainty.

 

Management’s plan regarding this matter is to, amongst other things, seek additional equity financing by selling our equity securities, obtaining funds through the issuance of debt. We cannot assure you that funds from these sources will be available when needed or, if available, will be on terms favorable to us or to our stockholders. If we raise additional funds or settle liabilities by issuing equity securities, the percentage ownership of our stockholders will be reduced, stockholders may experience additional dilution, or such equity securities may provide for rights, preferences or privileges senior to those of the holders of our common stock. Our ability to execute our business plan and continue as a going concern may be adversely affected if we are unable to raise additional capital or operate profitably.

 

The Company anticipates that further equity/debt financings will be necessary to continue to fund operations in the future and there is no guarantee that such financings will be available or, if available, on acceptable terms.

 

14
 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Cautionary Statements

 

This Form 10-K contains financial projections and other “forward-looking statements,” as that term is used in federal securities laws, about Imaging3, Inc.’s financial condition, results of operations and business. These statements include, among others, statements concerning the potential for revenues and expenses and other matters that are not historical facts. These statements may be made expressly in this Form 10-K. You can find many of these statements by looking for words such as “believes,” “expects,” “anticipates,” “estimates,” or similar expressions used in this Form 10-K. These forward-looking statements are subject to numerous assumptions, risks and uncertainties that may cause our actual results to be materially different from any future results expressed or implied by us in those statements. The most important facts that could prevent us from achieving our stated goals include, but are not limited to, the following:

 

  (a) volatility or decline of our stock price;
     
  (b) potential fluctuation in quarterly results;
     
  (c) our failure to earn revenues or profits;
     
  (d) inadequate capital to continue the business and barriers to raising the additional capital or to obtaining the financing needed to implement our business plans;
     
  (e) failure to commercialize our technology or to make sales;
     
  (f) changes in demand for our products and services;
     
  (g) rapid and significant changes in markets;
     
  (h) litigation with or legal claims and allegations by outside parties, causing us to incur substantial losses and expenses;
     
  (i) insufficient revenues to cover operating costs;
     
  (j) dilution in the ownership of the Company through the issuance by us of additional securities and the conversion of outstanding warrants, notes and other securities;
     
  (k) failure to obtain FDA approval for our new medical imaging device, which is still in its prototype stage; and

 

15
 

 

We cannot assure that we will be profitable. We may not be able to develop, manage or market our products and services successfully. We may not be able to attract or retain qualified executives and technology personnel. We may not be able to obtain customers for our products or services. Our products and services may become obsolete. Government regulation may hinder our business. Additional dilution in outstanding stock ownership will be incurred due to the issuance or exercise of more shares, warrants and other convertible securities.

 

Because the statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by the forward-looking statements. We caution you not to place undue reliance on the statements, which speak only as of the date of this Form 10-K. The cautionary statements contained or referred to in this section should be considered in connection with any subsequent written or oral forward-looking statements that we or persons acting on our behalf may make. We do not undertake any obligation to review or confirm analysts’ expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date of this Form 10-K or to reflect the occurrence of unanticipated events.

 

The following discussion should be read in conjunction with our financial statements and notes to those statements. In addition to historical information, the following discussion and other parts of this annual report contain forward-looking information that involves risks and uncertainties.

 

Current Overview

 

From January 2018 to June 2019, the Company has 1) completed a critical transition in leadership, recruiting a highly-experienced professional team, 2) established strategic partnering with leading regulatory, marketing and medical device R&D consulting organizations to support our objective of gaining 510(k) marketing clearance from the FDA for our lead product, the Dominion SmartScan™ system, 3) advanced constructive debt renegotiation with existing lenders, which resulted in several settlements in the second quarter of 2019 and July 2019, and 4) entered into a reverser merger share purchase agreement with Grapefruit Boulevard Investments, Inc. which was consummated July 10, 2019.

 

Beginning our efforts to establish strong strategic partners for regulatory, marketing and medical device R&D activities, in January 2018, we engaged the highly-regarded technology, strategy and marketing consultants of Halteres Associates to help define and lead the Company through critical strategy planning. In March 2018, we announced the selection of the Experien Group, a renowned medical device regulatory consultancy, to help lead our regulatory preparation and submission activities. The Experien Group have successfully assisted hundreds of companies like Imaging3 with their FDA submissions. In November 2018, we commenced work with a highly-experienced contract consulting team with particularly relevant radiology product R&D experience, on the evaluation and further instrument development planning around the Dominion SmartScan’s uniquely distinguishing algorithmic and software capabilities.

 

In preparation for fund-raising and a step-wise progression towards a later uplist to a major stock exchange, the Company announced the successful completion of a 1:20 reverse split in April of 2018, which addressed the Company’s capital and debt structure as we improve our ability to attract new capital. In May 2018, three of our note holders chose to complete the conversion of their debt investments entirely over into equity.

 

In the absence of FDA approval for our medical device, we currently do not and cannot rely upon it as a future source of sales and revenue. We are subject to the uncertainty of not knowing whether or when our proprietary medical device will be approved and can be sold. Under those circumstances, management believes that we will continue our current trend of incurring operating losses, requiring us to raise additional capital or financing from outside sources. We have raised $782,831 via equity and debt during 2018, and $988,500 during the six months ended June 30, 2019, sufficient to continue Company operations, and believe that we will be able to close on additional monies in the near future to accelerate progress on the Company’s stated plans. We cannot assure that we will be able to raise sufficient capital or financing to maintain our business while we are incurring operating losses, and we cannot assure that we will become profitable if our proprietary medical device is approved by the FDA.

 

16
 

 

Critical Accounting Policies

 

Our discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We monitor our estimates on an on-going basis for changes in facts and circumstances, and material changes in these estimates could occur in the future. Changes in estimates are recorded in the period in which they become known. We base our estimates on historical experience and other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from our estimates if past experience or other assumptions do not turn out to be substantially accurate.

 

We have identified the policies below as critical to our business operations and the understanding of our results of operations.

 

Stock-based Compensation

 

We measure and recognize compensation expense for all share-based payment awards made to employees and directors based on the grant date fair values of the awards. For stock option awards to employees with service and/or performance-based vesting conditions, the fair value is estimated using the Black-Scholes option pricing model. The value of an award that is ultimately expected to vest is recognized as expense over the requisite service periods in our statements of operations. Our stock-based awards are comprised principally of shares issued for services and stock options.

 

We account for stock options issued to non-employees in accordance with the guidance for equity-based payments to non-employees. Stock option awards to non-employees are accounted for at fair value using the Black-Scholes option pricing model. Management believes that the fair value of stock options is more reliably measured than the fair value of the services received. The fair value of the unvested portion of the options granted to non-employees is re-measured each period. The resulting increase in value, if any, is recognized as expense during the period the related services are rendered.

 

The Black-Scholes option pricing model requires management to make assumptions and to apply judgment in determining the fair value of our awards. The most significant assumptions and judgments include estimating the fair value of our underlying stock, the expected volatility and the expected term of the award. In addition, the recognition of stock-based compensation expense is impacted by estimated forfeiture rates

 

Revenue Recognition

 

Effective January 1, 2018, the Company adopted the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 supersedes the revenue recognition requirements in FASB Accounting Standards Codification (“ASC”) 605, Revenue Recognition, and is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. It also requires additional disclosure about the nature, amount, timing, and uncertainty of revenue, cash flows arising from customer contracts, including significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. The adoption of ASU 2014-09, using the modified retrospective approach, had no significant impact on the Company’s results of operation, cash flows or financial position.

 

Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products or providing services. All revenue is recognized when the Company satisfies its performance obligations under the contract. The majority of the Company’s contracts have a single performance obligation and are short term in nature. Generally, the Company extends credit to its customers and does not require collateral. The Company performs ongoing credit evaluations of its customers and historic credit losses have been within management’s expectations. The Company has a revenue receivables policy for service and warranty contracts. Equipment sales usually have a one-year warranty of parts and service. After a one-year period, the Company contacts the buyer to initiate the sale of a new warranty contract for one year. Warranty revenues are deferred and recognized on a straight-line basis over the term of the contract or as services are performed.

 

17
 

 

Research and Development

 

Costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with FASB ASC 730-10. Included in research and development costs are operating costs, facilities, supplies, external services, clinical trial and manufacturing costs, and overhead directly related to the Company’s research and development operations, as well as costs to acquire technology licenses.

 

Other Accounting Factors

 

The effects of inflation have not had a material impact on our operation, nor are they expected to in the immediate future.

 

The following sets forth selected items from our statements of operations for six months ended June 30, 2019 and for the six months ended June 30, 2018.

 

    Six Months
Ended
June 30, 2019
    Six Months
Ended
June 30, 2018
 
Net revenues   $ -     $ -  
Cost of goods sold     -       -  
Gross Profit     -       -  
General and administrative expenses     880,550       6,006,236  
Income (loss) from operations     (880,550 )     (6,006,236 )
Total other income (expenses)     (1,328,273 )     (1,589,073 )
Provision for income taxes     -       (800 )
Net income (loss)   $ (2,208,823 )   $ (7,596,109 )

 

Results of Operations for the Six Months Ended June 30, 2019 as compared to the Six Months Ended June 30, 2018.

 

During the six months ended June 30, 2019, we were focusing on our development stage medical device efforts. Our legacy C-arm activity from prior years was completely wound down in 2017. Accordingly, we had no revenues or cost of goods sold for the six months ended June 30, 2019 and 2018.

 

Our operating expenses decreased from $6,006,236 in 2018 to $880,550 for the six months ended June 30, 2019, a decrease of 85% primarily as a result of stock-based compensation and outside consulting activity.

 

The Company’s other expenses fluctuates as a result of derivative liability activity and the extinguishment of debt. Currently, our net loss for the six months ended June 30, 2019 was $2,208,823 as compared to a net loss of $7,595,309 for the six months ended June 30, 2018.

 

We expect the trend of operating losses by us to continue into the future at the current or greater rate as we spend money on product development and marketing. We cannot assure that we can achieve profitability. We do not expect litigation against us to expand, although we can give no assurances in relation to future litigation.

 

    Three Months
Ended
June 30, 2019
    Three Months
Ended
June 30, 2018
 
Net revenues   $ -     $ -  
Cost of goods sold     -       -  
Gross Profit     -       -  
General and administrative expenses     685,255       334,939  
Income (loss) from operations     (685,225 )     (334,939 )
Total other income (expenses)     14,403,428       (530,967 )
Provision for income taxes     -       (800 )
Net income (loss)   $ 13,718,203     $ (866,706 )

 

18
 

 

Results of Operation for the Three Months Ended June 30, 2019 Compared to the Three Months Ended June 30, 2018

 

Our operating expenses increase from $334,939 in 2018 to $685,255 for the three months ended June 30, 2019, a increase of 105% primarily as a result of stock-based compensation and outside consulting activity.

 

The Company’s other expenses fluctuates as a result of derivative liability activity and the extinguishment of debt. Currently, our net gain for the three months ended June 30, 2019 was $13,718,203 as compared to a net loss of $866,706 for the three months ended June 30, 2018.

 

Liquidity and Capital Resources

 

Our total current assets increased to $311,589 as of June 30, 2019, from $14,214 as of December 31, 2018. The cash and cash equivalent accounts as of June 30, 2019 were $47,539 compared to $14,214 as of December 31, 2018.

 

Our total current liabilities decreased to $4,946,732 as of June 30, 2019 from $5,324,379 as of December 31, 2018. The $377,647 decrease is due to a reduction of notes payable in the amount of $1,547,189 offset by the increase in the subscription payable of $1,571,396 for the six months ended June 30, 2019.

 

The cash account as of June 30, 2019 was $47,539 compared to $14,214 as of December 31, 2018. Cash raised through financing activities was expended primarily on day-to-day business operations and general and administrative expenses.

 

During the six months ended June 30, 2019, we used $955,175 of net cash for operating activities, as compared to $507,623 used during the six months ended June 30, 2018. Net cash provided by financing activities for the six months ended June 30, 2019 was $988,500, as compared to $508,223 during the six months ended June 30, 2018.

 

We expect our working capital requirements in the next twelve months to be met primarily by the proceeds of private placements of common stock, convertible instruments and other securities to our existing shareholders and other investors. We expect to need additional working capital from outside sources to cover our anticipated operating deficits and to finance the re-filing of our application to the FDA for our proprietary 3D medical imaging device. There is no assurance that the Company will be able to raise sufficient additional capital or financing to continue in business or to effectively execute its business plan.

 

Going Concern Qualification

 

We have incurred significant losses from operations, and such losses are expected to continue. In their report on our financial statements as of and for the period ended December 31, 2018, our auditors have expressed substantial doubt about our ability to continue as a going concern. In addition, we have limited working capital. The foregoing raises substantial doubt about our ability to continue as a going concern. Management’s plan includes, among other things, seeking additional equity financing by selling our equity securities, obtaining funds through the issuance of debt. We cannot guarantee that additional capital and/or debt financing will be available when and to the extent required, or that if available it will be on terms acceptable to us. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The “Going Concern Qualification” may make it substantially more difficult for us to raise capital.

 

19
 

 

Off-Balance Sheet Arrangements

 

None.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

Not applicable.

 

Item 4. Controls and Procedures

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended. Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2018. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control-Integrated (2013Framework). A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. We have identified the following material weaknesses:

 

1. As of June 30, 2019, we did not maintain effective controls over financial statement disclosure. Specifically, controls were not designed and in place to ensure that all disclosures required were originally addressed in our financial statements. Accordingly, management has determined that this control deficiency constitutes a material weakness.

 

2. As of June 30, 2019, we did not maintain adequate segregation of duties. Accordingly, management has determined that this control deficiently constitutes a material weakness.

 

Because of these material weaknesses, management has concluded that we did not maintain effective internal control over financial reporting as of June 30, 2019, based on the criteria established in “Internal Control-Integrated Framework” issued by the COSO.

 

Changes in Internal Control Over Financial Reporting

 

There have been no changes in our internal control over financial reporting through the date of this report or during the six months ended June 30, 2019, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

This report does not include an attestation report from our registered public accounting firm regarding internal control over financial reporting.

 

20
 

 

PART II. OTHER INFORMATION

 

Item 1A. Risk Factors

 

Not applicable because we are a smaller reporting company.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

There were no unregistered sales of equity securities during the period covered by this quarterly report.

 

Item 3. Defaults Upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

Not Applicable.

 

Item 5. Other Information

 

On July 25, 2019, the Company appointed Kenneth J Biehl as Chief Financial Officer.

 

Item 6. Exhibits

 

(a) Exhibits

 

EXHIBIT NO.   DESCRIPTION
     
31.1   Section 302 Certification of Chief Executive Officer
31.2   Section 302 Certification of Chief Financial Officer
32.1   Section 906 Certification
32.2   Section 906 Certification
101.INS   XBRL Instance Document
101.SCH   XBRL Taxonomy Extension Schema Document
101.CAL   XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF   XBRL Taxonomy Extension Definition Linkbase Document
101.LAB   XBRL Taxonomy Extension Label Linkbase Document
101.PRE   XBRL Taxonomy Extension Presentation Linkbase Document

 

21
 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

 

/s/ Bradley J. Yourist   Dated: August 14, 2019
Bradley J. Yourist    
Chief Executive Officer    
     
/s/ K. J. Biehl   Dated: August 14, 2019
Kenneth J. Biehl    
Chief Financial Officer    

 

22
 

 

Imaging3, Inc. (USOTC:IGNG)
Historical Stock Chart

1 Year : From Dec 2018 to Dec 2019

Click Here for more Imaging3, Inc. Charts.

Imaging3, Inc. (USOTC:IGNG)
Intraday Stock Chart

Today : Saturday 14 December 2019

Click Here for more Imaging3, Inc. Charts.

Latest IGNG Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.